The role of systemic inflammation in the pathogenesis and progression of nonalcoholic fatty liver disease in children
Background. Progression of nonalcoholic fatty liver disease occurs in genetically predisposed children due to the development of systemic and local inflammatory response in the liver parenchyma closely related to the formation of insulin resistance. The accumulated data indicates that patients with nonalcoholic fatty liver disease are characterized by a high level of serum inflammatory markers. The aim of the present study was to establish the relationship between blood lipids, insulin resistance, anthropometric data, indicators of systemic inflammation and the degree of liver steatosis in children with nonalcoholic fatty liver disease; to assess the role of tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), interleukin-10 in the progression of nonalcoholic fatty liver disease in children. Materials and methods. We examined 34 children aged 6–17 years. Determination of the presence and degree of hepatic steatosis was made using FibroScan® 502-touch with evaluation of the controlled attenuation parameter (CAP). Patients were divided into 3 groups according to CAP level: a control group (S0) consisted of 21 patients without hepatic steatosis (61.8 %), group S1 — 4 persons with grade 1 steatosis (11.8 %), group S2 — 4 patients with grade 2 steatosis (11.8 %), group S3 — 5 individuals with grade 3 steatosis (14.8 %). All patients underwent anthropometric measurements, blood tests with determination of erythrocyte sedimentation rate, level of leukocytes and leukocyte formula. We studied levels of the IL-6, IL-10, TNF-α, insulin in the blood serum, also serum samples were tested for total cholesterol, triglycerides (TG), high density lipoprotein (HDL) cholesterol with calculation of low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL) levels, atherogenic index. Results. Obesity and overweight were observed in 100 % of children in S1. S2, S3 groups, and in 47.6 % of patients without steatosis (S0 group) (p < 0.05). We revealed that S3 group was characterized by higher average levels of white blood cells (7.13 ± 0.51 g/l) and erythrocyte sedimentation rate (15.50 ± 4.04 mm/h) compared with S0 group (5.34 ± 1.17 g/l, 10.19 ± 7.74 mm/h, respectively; p < 0.05).We found that insulin level increased with growth of steatosis grade: in group S0 — by 1.3 times, group S1 — by 2.4 times, group S2 — by 2.8 times and in S3 group — by 6.3 times compared to the controls. Also, we found a presence of significant differences between the content of HDL cholesterol in groups S3 and S0. The level of TG (r = 1.0;
p < 0.05) and VLDL (r = 0.8; p = 0.04) positively correlated with the level of insulin, and showed a negative correlation with HDL level (r = –0.7; p < 0.05). Maximum levels of TNF-α were observed in group S3 (1.8 ± 0.8 pg/ml), which differed significantly from S0 group and other groups with steatosis. The level of IL-6 increased progressively with growth of steatosis grade: S0 — 1.2 ± 0.2 pg/ml, S1 — 1.55 ± 0.30 pg/ml, S2 — 4.8 ± 0.5 pg/ml, S3 — 6.1 ± 0.5 pg/ml. Level of anti-inflammatory cytokine IL-10 changed ambiguous: the minimum level of this index was in S1 group, that was significantly lower comparing to S0 group. The concentration of IL-10 reached maximum value in S2 group (9.5 ± 1.1 pg/ml)
and critically decreased in patients from S3 group. Conclusions. Nonalcoholic fatty liver disease in children manifested by imbalance of pro- and anti-inflammatory cytokines with increase of IL-6, TNF-α and decrease in IL-10 level was associated with the grade of hepatic steatosis on the background of dyslipidemia and insulin resistance.
Full Text:PDF (Українська)
Pacifico L, Anania C, Martino F, Poggiogalle E, Chiarelli F, Arca M, et al. Management of metabolic syndrome in children and adolescents. Nutrition, Metabolism and Cardiovascular Diseases. 2011 Jun; 21(6): 455-66. doi: 10.1016/j.numecd.2011.01.011.
WHO. The WHO nutrition policy [Online]. 2015. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/policy.
Stepanov YM., Abaturov OE, Zavgorodnyaya NY, Skyrda IY. Nonalcoholic fatty liver disease in children (Part I): current approaches to diagnosis and treatment. Gastrojenterologija. 2015;2(56): 99-107. (In Ukrainian).
Feliciano Chanana Paquissi. Immune Imbalances in Non-Alcoholic Fatty Liver Disease: From General Biomarkers and Neutrophils to Interleukin-17 Axis Activation and New Therapeutic Targets. Frontiers in Immunology. 2016;7(490):1-13. doi:10.3389/fimmu.2016.00490.
Stepanov YM, Abaturov OE, Zavgorodnyaya NY, Skyrda IY. Nonalcoholic fatty liver disease in children: a modern view on the diagnosis ans treatment (II part). Gastrojenterologija. 2015;3(57):122-31. (In Ukrainian).
Rolo AP, Teodoro JS, Palmeira CM. Role of oxidative stress in the pathogen-esis of nonalcoholic steatohepatitis. Free Radic Biol Med. 2012 Jan;52(1):59-9. PMID: 22064361. doi: 10.1016/j.freeradbiomed.2011.10.003 89.
Okazaki I, Noro T, Tsutsui N, Yamanouchi E, Kuroda H, Nakano M, et al. Fibrogenesis and carcinogenesis in nonalcoholic steatohepatitis (NASH): involvement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinase (TIMPs). Cancers (Basel). 2014;6:1220-55. doi: 10.3390/ cancers6031220.
Mi YQ, Shi QY, Xu L, Shi RF, Liu YG, Li P, et al. Controlled attenuation parameter for noninvasive assessment of hepatic steatosis using Fibroscan®: validation in chronic hepatitis B. Digestive diseases and sciences. 2015;60(1):243-51. doi: 10.1007/s10620-014-3341-x.
WHO. The WHO child growth standards website [Online]. 2006. Available from: http://www.who.int/childgrowth/en/
Fernández JR, Redden DT, Pietrobelli A, Allison DB. Waist circumference percentiles in nationally representative samples of African-American, European-American, and Mexican-American children and adolescents. The Journal of pediatrics. 2014;145(4):439-44. PMID: 15480363. doi: 10.1016/j.jpeds.2004.06.044.
Das SK, Balakrishnan V, Mukherjee S, Vasudevan DM. Evaluation of blood oxidative stress related parameters in alcoholic liver disease and non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2008;68(4): 323-34. PMID: 18609067. doi: 10.1080/00365510701673383.
Yamaguchi K, Nishimura T, Ishiba H, Seko Y, Okajima A, Fujii H, et al. Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high‐fat diet fed mice. Liver International. 2015;35(2):550-61. PMID: 25066281. doi: 10.1111/liv.12645.
Akinobu T, Kawai K, Yamamoto D. Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH). International Journal of Molecular Sciences. 2013 Oct;14(10):20704-20728. doi: 10.3390/ijms141020704.
Alberti KG, Eckel RH, Grundy SM. Harmonizing the metabolic syndrome: Task Force on Epidemiology and prevention - statement of the International Diabetes Federation; National Heart, Lung, and Blood Institute; American Heart Association; Heart Federation; International Atherosclerosis Society; and International Association for Study of Obesity. Circulation. 2009 Oct;120(16):1640-5. PMID: 19805654. doi: 10.1161/CIRCULATIONAHA.109.192644.
Joseph L, Gokce N. Adipose macrophage infiltration is associated with insulin resistance and vascular endothelial dysfunction in obese subjects. Arterioscler Thromb Vasc. 2008;28:1654-9. PMID: 18566296. doi: 10.1161/ATVBAHA.108.170316.
Fusman G, Mardi T, Justo D, et al. Red blood cell adhesiveness/aggregation, C-reactive protein, fbrinogen, and erythrocyte sedimentation rate in healthy adults and in those with atherosclerotic risk factors. Am J Cardiol. 2002;90:561-3. doi: 10.1016/S0002-9149(02)02539-0.
Ustyol A, Aycan Ustyol E, Gurdol F. P-selectin, endocan, and some adhesion molecules in obese children and adolescents with non-alcoholic fatty liver disease. Scand J Clin Lab Invest. 2017;77(3):205-9. doi: 10.1080/00365513.2017.1292363.
- There are currently no refbacks.
Copyright (c) 2017 CHILD`S HEALTH
This work is licensed under a Creative Commons Attribution 4.0 International License.
© Publishing House Zaslavsky, 1997-2017